BCT 1901 (CAPTURE): A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.

Breast Cancer Trials0 个研究点目标入组 66 人开始时间: 2019年8月12日最近更新: 2023年12月4日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方: Breast Cancer Trials
入组人数: 66

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment
盲法: Open (masking not used)

入排标准

年龄范围: 18 Years 至 o limit（—）
性别: All

入选标准

•PRE-SCREENING
•For inclusion in the pre-screening, participants must fulfil all the following criteria:
•1. Female or Male, >= 18 years.
•2. Advanced (locoregionally recurrent not amenable to curative therapy, or metastatic) ER-positive, HER2-negative breast cancer, histologically defined as:
•a. ER positive: Locally assessed oestrogen receptor status based on assessment of primary or metastatic disease. ER-positive is defined as >=10% (any PR expression) by immunohistochemistry irrespective of staining intensity.
•b. HER2 negative:
•i. IHC 1+, as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of invasive tumour cells; OR
•ii. IHC 0, as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within <= 10% of the invasive tumour cells; OR
•iii. ISH (FISH or SISH) negative based on:
•* Single-probe average HER2 copy number < 4.0 signals/cell, OR
•* Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy number < 4.0 signals/cell.
•3. ECOG performance status of 0–1.
•4. No more than two prior lines of endocrine therapy for treatment of advanced disease setting (no prior fulvestrant).
•5. No more than one line of chemotherapy for treatment of advanced breast cancer (no prior capecitabine).
•RANDOMISATION
•In addition to the above listed pre-screening inclusion criteria, participants must fulfil all of the following criteria prior to randomisation:
•1. PIK3CA mutation (PIK3CA E542K, E545K, H1047L or H1047R mutation) identified through ctDNA testing.
•2. Progression of disease during or after CDK4/6 inhibitor (i.e. ribociclib, palbociclib, abemaciclib) AND AI therapy (i.e. letrozole, anastrozole, exemestane) in the (neo) adjuvant OR advanced disease setting.
•3. Evaluable disease (i.e. at least one measurable or non-measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
•4. Adequate organ function:
•a. Haematology: Absolute neutrophil count >= 1.5 × 10^9/L, Platelets >= 90 × 10^9/L, Haemoglobin >= 9.0 g/dL
•b. Hepatic Function:
•i. In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 × ULN. If the participant has liver metastases, ALT and AST <= 5 × ULN. In addition, the elevated ALT or AST values must be stable for 2 weeks without evidence of biliary obstruction by imaging;
•ii. Total bilirubin < 2 x ULN (any elevated bilirubin should be asymptomatic at screening)except for participants with Gilbert’s syndrome who may only be included if the total bilirubin is <= 3.0 × ULN or direct bilirubin <= 1.5 × ULN.
•c. Renal Function; Creatinine Clearance >= 35 mL/min using Cockcroft-Gault formula;
•d. Calcium (corrected for serum albumin) and magnesium with normal limits or <= Grade 1 according to NCI-CTCAE V5.0 if judged clinically not significant by the investigator;
•e. Potassium within normal limits, or corrected with supplements;
•f. Blood Chemistry;
•i. Fasting plasma glucose (FPG) <= 6.0 mmol/L and Glycosylated Haemoglobin (HbA1c) <= 6.5% (both criteria have to be met);
•ii. Fasting Serum amylase <= 2 × ULN;
•iii. Fasting Serum lipase <= ULN.
•5. Participants with metastatic CNS tumours may participate in this study if they are:
•a. Four weeks from completion of prior therapy for CNS disease (including radiation and surgery) to starting study treatment;
•b. Clinically stable with respect to the CNS tumour at the time of screening as determined by cl

排除标准

•1. Any disease burden that makes participants ineligible for endocrine therapy as per the investigator’s best judgement.
•2. Prior treatment with capecitabine, fulvestrant, any PI3K, mTOR or AKT inhibitor.
•3. Known hypersensitivity or contra-indication to alpelisib, fulvestrant or capecitabine.
•4. Concurrently using other anti-cancer therapy. Exception: goserelin.
•5. Previous or concomitant invasive malignancy. The exceptions are:
•a. participants with non-breast malignancy >= 3 years ago, treated with curative intent and without evidence of recurrence;
•b. basal or squamous cell carcinoma of the skin or non-melanomatous skin cancer;
•c. in situ carcinoma without invasion (includes in situ breast carcinoma);
•d. curatively resected cervical cancer.
•6. Radiotherapy <= 2 weeks prior to randomisation, and who has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia).
•7. Prior endocrine therapy <= 2 weeks prior to randomisation. Exception: goserelin.
•8. Prior chemotherapy <= 2 weeks prior to randomisation.
•9. Surgery <= 2 weeks prior to randomisation or has not recovered from major side effects.
•10. Not recovered from all toxicities related to prior anticancer therapy to NCI-CTCAE V5.0 Grade <= 1. Exception: patients with any grade of alopecia or menopausal symptoms.
•11. Participation in a prior investigational study within 30 days prior to the start of study treatment or within 5 half-lives of the investigational product, whichever is longer.
•12. Established diagnosis of type I diabetes mellitus, type II diabetes mellitus requiring anti-hyperglycaemic medication or any participant with HbA1c > 6.5%.
•13. Currently documented pneumonitis/interstitial lung disease.
•14. Child Pugh score B or C.
•15. Clinically significant, uncontrolled heart disease and/or recent cardiac events including any of the following:
•a. History of angina pectoris, coronary artery bypass graft (CABG), symptomatic pericarditis, or myocardial infarction within 6 months prior to the start of study treatment;
•b. History of documented congestive heart failure (New York Heart Association functional classification III-IV);
•c. Left Ventricular Ejection Fraction (LVEF) < 50% as determined by echocardiogram (ECHO);
•d. Clinically significant cardiac arrhythmias, (e.g. ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g. bifascicular block, Mobitz type II and third degree AV block without pacemaker in place);
•e. Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) >= 160 mmHg and/or Diastolic Blood Pressure (DBP) >= 100 mm Hg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening;
•f. Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or corrected QT interval > 470msec at screening (using Fridericia correction);
•g. Bradycardia (heart rate < 50 at rest), by ECG or pulse.
•16. History of acute pancreatitis within 1 year of screening or a past medical history of chronic pancreatitis.
•17. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs based on investigator discretion.
•18. Known history of Human Immunodeficiency Virus (HIV) infection (testing not mandatory).
•19. Other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung, etc.) that would prevent prolo

研究者

发起方

Breast Cancer Trials

相似试验

招募中

2 期

In patients with previously untreated early stage triple negative breast cancer, how well does using Nivolumab or Nivolumab + Relatlimab before starting standard chemotherapy, OR starting treatment with Nivolumab and chemotherapy at the same time, help to reduce tumour size before surgery compared?Triple negative breast cancerCancer - Breast

ACTRN12619001308189Breast Cancer Trials162

已完成

2 期

Permissive HyperthErmiA Through Avoidance of Paracetamol in Known or Suspected Infection in the Intensive Care Unit (ICU)Known or suspected infection in critically ill patients in the Intensive Care Unit (ICU)Infection - Studies of infection and infectious agents

ACTRN12612000513819Medical Research Institute of New Zealand700

进行中（未招募）

1 期

A phase II randomised study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with ER+ primary breast cancer.ER positive, HER2 negative early invasive breast cancerMedDRA version: 18.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-000887-16-GBThe Royal Marsden NHS Foundation Trust306

进行中（未招募）

1 期

A clinical study to evaluate the safety and efficacy of rivaroxaban in patients with mildCOVID-19 that are at high risk of serious complications such as blood clots that can formin the organs of the body. It is hoped that by intervening early with a drug which thinsthe blood that may prevent progression of mild symptoms to serious complications andsevere disease.

EUCTR2020-005395-35-GBBill & Melinda Gates Medical Research Institute600

进行中（未招募）

1 期

EUCTR2020-002195-12-ITBioNTech SE120